Day One Biopharmaceutical Valuation Multiples

Day One Biopharmaceutical Overview

About Day One Biopharmaceutical

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

Founded

2018

HQ

Employees

178

Website

dayonebio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $176M

EBITDA: ($116M)

EV

$892M

Valuation Multiples

Multiples.vc

Start free trial

Day One Biopharmaceutical Financials

Day One Biopharmaceutical reported last 12-month revenue of $176M and negative EBITDA of ($116M).

In the same LTM period, Day One Biopharmaceutical generated $157M in gross profit, ($116M) in EBITDA losses, and had net loss of ($102M).

Day One Biopharmaceutical P&L

In the most recent fiscal year, Day One Biopharmaceutical reported revenue of $158M and EBITDA of ($124M).

Day One Biopharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Day One Biopharmaceutical Stock Performance

Day One Biopharmaceutical has current market cap of $1B, and enterprise value of $892M.

Day One Biopharmaceutical's stock price is $12.88.

Day One Biopharmaceutical Valuation Multiples

Day One Biopharmaceutical trades at 5.1x EV/Revenue multiple, and (7.7x) EV/EBITDA.

Day One Biopharmaceutical Financial Valuation Multiples

As of March 18, 2026, Day One Biopharmaceutical has market cap of $1B and EV of $892M.

Equity research analysts estimate Day One Biopharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Day One Biopharmaceutical has a P/E ratio of (13.0x).

Day One Biopharmaceutical Margins & Growth Rates

Day One Biopharmaceutical's revenue in the last 12 month grew by 45%.

Day One Biopharmaceutical's revenue per employee in the last FY averaged $1.0M.

Day One Biopharmaceutical's rule of 40 is (21%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Day One Biopharmaceutical's rule of X is 47% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Day One Biopharmaceutical Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Day One Biopharmaceutical M&A Activity

Day One Biopharmaceutical acquired XXX companies to date.

Last acquisition by Day One Biopharmaceutical was on XXXXXXXX, XXXXX. Day One Biopharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Day One Biopharmaceutical Investment Activity

Day One Biopharmaceutical invested in XXX companies to date.

Day One Biopharmaceutical made its latest investment on XXXXXXXX, XXXXX. Day One Biopharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).